accelerate discovery. amplify returns. 2020 event overview.pdf · santen pharmaceutical co. santen...

2020 EVENT OVERVIEW

ACCELERATE Discovery.AMPLIFY Returns.

INVESTORFORUM

October 13-14, 2020The Westin St. Francis • San Francisco, CA

REGISTRATION WILL OPEN IN SUMMER 2020

GAIN ACCESS TO BIO ONE-ON-ONE

PARTNERING™ for scouting potential investments and deal

partners, optimizing your time at the event.

EXPERIENCE THE BEST

OF BIOTECH with two-days of productive

partnering meetings with institutional investors, industry analysts, and senior biotechnology

executives, in one location.

GET THE PULSE of the current and proposed

investment trends in biotechnology.

LEARN ABOUT THE

HOTTEST CLINICAL DEVELOPMENTS

and industry catalysts by attending the conference’s therapeutic and business-

focused panel discussions.

EVALUATE FRESH INVESTMENT

OPPORTUNITIES including compatible,

complementary, and competitive

companies.

UNIQUE PLATFORM FOR YOUR COMPANY

to highlight accomplishments and discuss upcoming

milestones. Approximately 170 companies will be chosen

based on a selection process evaluating a company’s

pipeline and R&D activities.

NETWORK with peers, investors, and potential partners

attending the conference and our exclusive

receptions.

EXCLUSIVE SPONSORSHIP

OPPORTUNITIES to showcase thought

leadership, elevate brand identity and maximize

partnering benefits with an elite audience.

ATTEND FIRESIDE CHATS with senior business

leaders who will share their recent company successes, what keeps the C-suite up

at night, and where the industry’s leading

companies are headed in 2021.

Event Attributes and Opportunities

The BIO Investor Forum is an international biotech investor conference dedicated to showcasing drug development programs that are ready for partnering or venture funding and those poised to join the growth “watch list” in 2021. Since its inception 18 years ago, the BIO Investor Forum has become the premier event where biotech innovators can find investors and strategic partners to advance their company to the next stage in their business life cycle.

#BIF20 • bio.org/investorforum1

http://bio.org/investorforum

Like being at JPM without the crowds.

Companies by Type

42%25%

33% c Biopharmac Investor

c Other

NeoplasmAll OthersMusculoskeletal disease

Genetic disorderPsychiatric disorder

Ocular diseaseGenitourinary diseaseRespiratory disease

Metabolic disorder

Hematological disease

Degeneration

Endocrine diseaseDermatological disease

Immune disorder Gastrointestinal disease

Neurological disease

Infectious disease

Inflammatory disease

Cardiovascular disease

Companies by Primary Therapeautic Area

14%7%

8%

7%

7%6%

6%6%5%5%

4%4%

4%4%

3%3%

3%2%2%

1% Sell-Side Research1% Venture Philanthropy

Family OfficeOther

Investment Bank1% Endowment/Foundation

1% Investor (buy-side or sell-side research)

Royalty/Debt Financing

Hedge/Mutual Fund (PM, Buy-Side Research)

Angel Investing

VC/Corporate VC

Investors by Investor Type

62%9%

7%

6%5%

4% 3%

Audience Demographics



0

100

200

300

400

500

600

9191 9191 111111

115

115

115

115 116

116 121

121

127

127

134

134

137

137 143

143

152

152 158

158

162

162 19

319

3 214214

217

217 233

233

244

244 25

925

9

338

338 35

835

8

359

359 376

376

592

592

Cent

ral n

ervo

us

syst

em di

seas

eAg

ing

Alzh

eimer

s dise

ase

Mus

culo

skele

tal d

iseas

eLe

ukem

iaFi

bros

isDe

gene

ratio

nLy

mph

oma

Resp

irato

ry di

seas

e

Hem

atol

ogica

l dise

ase

Auto

imm

une d

iseas

e

Derm

atol

ogica

l dise

ase

Ocul

ar D

iseas

e

Adva

nced

solid

tum

orGe

netic

diso

rder

Met

abol

ic di

sord

erSo

lid Tu

mor

Card

iova

scul

ar di

seas

eIm

mun

e diso

rder

Gast

roin

test

inal

dise

ase

Infe

ctio

us di

seas

eNe

urol

ogica

l dise

ase

Infla

mm

ator

y dise

ase

Neop

lasm

Canc

er

TOP THERAPEUTIC AREAS FOR SCHEDULED MEETINGS

BIO Investor Forum at a Glance

170PRESENTING COMPANIES

350 EARLY-STAGE

INVESTORS

712 COMPANIES

SHOWCASING DRUG DEVELOPMENT

3,150 BIO ONE-ON-ONE

PARTNERING MEETINGS



The session, Advice on Pitching Family Offices, Venture Philanthropies, and Other

Non-Private Equity Funding Sources, featured experienced voices, including

Reza Halse, MRLV, and Charlotte Hubbert, Gates Foundation Venture Capital, among

others, explaining the strategies to employ and properly satisfy a potential investor’s

expectation and secure the desired capital.

Day one of the event wrapped up with a networking reception for all attendees on the top floor of the Tower Building at the Westin St. Francis.Fireside Chat with Lon Cardon, PhD, Chief Strategy Officer, BioMarin

The opening plenary, Public Policy Outlook on Biotech Investment in

China, featuring Helen Chen with L.E.K. Consulting and James Huang,

Kleiner Perkins Caufield & Byers China; Panacea Venture, explored how

biotech companies can continue to raise capital, the proposed rulemaking

from CFIUS in the coming months, and a pathway for companies to

remain innovative while CEOs and investors navigate these changes.

During the panel, The Next Wave of Cancer Therapies: Allogenic Cell Therapies and Other Pioneers, Rafael Amado, MD, Allogen and others reviewed emerging treatment options in cancer, including the next wave of CAR-T, NK cell, and other pioneering approaches, highlighting promises enabled by each and the challenges to be resolved on the path to approvals and helping patients worldwide.

The event welcomed industry thought leaders discussing the latest in cancer treatments, gene therapies, CNS drug development, molecular diagnostics as well as business themes including board diversity, CFIUS, the IPO market, policy outlook, and investor engagement best practices. Other sessions looked at the ever-increasing digital space including applying artificial intelligence to improve therapy development.

2019 BIO Investor Forum Program Recap

As more biotechnology executives begin to focus on strategies to diversify their boards to avoid groupthink and strengthen corporate governance, an emerging consensus is forming that initial public offerings are a key gateway to assembling higher-performing leadership teams. That was the unanimous consensus of the industry experts who led the panel: Recruiting Talent to Meet Corporate Board Requirements and Representation Goals. This topic was especially timely for biotech companies headquartered in California, which became the first state to require that publicly traded corporations include at least one woman on their boards.



2019 Participating Investors

Below is a representative list of participating investment firms and sell side research analysts for the 2019 BIO Investor Forum.3E BioventuresAbbVieABES Venture PartnersAbingworth ManagementAccelerator Life Science PartnersAcuris PartnersAdjuvantAgent CapitalAgilent TechnologiesAleph CapitalAlexandria Venture InvestmentsAlignment VenturesAltamont Pharmaceutical HoldingsAltitude Life Science VenturesAndreessen HorowitzAquilo CapitalArch Venture PartnersArix BioscienceARTIS VenturesAsahi Kasei AmericaAsajes MedicalAsajes VenturesAsset Management VenturesAstellas Innovation Management Astellas Pharma USAstellas Venture ManagementATEL VenturesAtheneos VenturesBand of AngelsBarbara LaveryBeacon CapitalBiocoast CapitalBioIdeationsBiomark CapitalBioPacific InvestorsBios PartnersBiotech Alliances InternationalBohe Angel FundBorex CapitalBoryung HoldingsBOSON Capital PartnersBrace Pharma CapitalBrain Trust Accelerator FundBridgeBio PharmaBTIGCanadian Imperial Bank

of CommerceCapital Family OfficeCato BioVenturesCEC CapitalCenova CapitalChaperone InvestmentChina GrandCI InvestmentsCiplaCoventry EnterprisesCowin CapitalCrosswave ManagementCRVCSC LeasingDabar Investment AssociatesDalton InvestmentDanaher Life SciencesData Collective Venture Capital

DAYLI PartnersDCVC BioDefta PartnersDHVCDigiTx PartnersDolby Family VenturesDorset CapitalDoubleLine CapitalDynamk CapitalEast West BankEisaiEmerson CollectiveEsousa HoldingsFMG VenturesF-Prime Capital PartnersFujifilm Diosynth BiotechnologiesG4S CapitalGE VenturesGenoa VenturesGlobal Neurohealth VenturesGreenSky CapitalGrey Sky Venture PartnersHannol VenturesHbm PartnersHCM Healthcare Capital ManagementHealthCare Royalty PartnersHEDA VenturesHelicase VentureHelix VenturesHemi VenturesHercules CapitalHone CapitalIaso VenturesIllumina AcceleratorIllumina VenturesIn CapitalInbio VenturesINCJIntegral GroupIntuitiveIPF PartnersJHBioJohnson & Johnson Development

CorporationJoyance PartnersJulz CoJuvenile Diabetes Research

Foundation (JDRF)KB Financial GroupKyoto University Innovation CapitalLaguna VenturesLaurel Venture CapitalLife Science AngelsLilly Asia VenturesLincoln Park CapitalLumira VenturesLyfe CapitalLymo VenturesLYZZ Capital AdvisorsMatthews AsiaMatthews International Capital

ManagementMaywell CapitalMDB Capital Group

MedImmune VenturesMilestone CapitalMitsui & Co. Global InvestmentMomentum BiotechMPM CapitalMSQ VenturesMyBioGateNan Fung Life SciencesNanoDimensionNCL Technology VenturesNew Enterprise Associates (NEA)Nomura InstinetNorthern Light Venture CapitalNovo Ventures (US)OCVOlive Tree CapitalOresund CapitalOSF Healthcare VenturesOtsuka Pharmaceutical Co.Oxford FinancePalo Alto InvestorsPanacea Venture HealthcarePappas VenturesPerserverance CapitalPharmstandard JSCPivotal BioVenture PartnersPoC CapitalPremier PartnersPresidio PartnersPrevail PartnersPrimer CapitalQiming Venture Partners VSAQuadriga BiosciencesQuan CapitalRBV CapitalRelentless Pursuit PartnersRemiges VenturesResearch Bridge PartnersRoche Venture FundSanderling VenturesSandhill AngelsSanofi

Santen Pharmaceutical Co.Santen VenturesSatter Medical Technology

PartnershipShanghai Henlius BiotechShenzhen Salubris PharmaceuticalsSimcere Pharmaceutical GroupSinar Mas TechnologySofinnova VenturesSPRIM VenturesSR OneStarLink CapitalStartUp HealthSteel Wolf VenturesTaiho VenturesTaiwania CapitalTakeda VenturesTalfinium InvestmentsThe Benchmark CompanyThe Leukemia & Lymphoma SocietyTosoh USATransPacific Venture Capital PartnersTriple Ring TechnologiesUltreum CapitalVantagePoint Capital PartnersvenBio PartnersVertex Venture HoldingsVivo CapitalVoya FinancialW Global CapitalWARF TherapeuticsWashington Research Foundation

CenterWBB SecuritiesWestlake VenturesWI Harper GroupXeraya Capital Life VentureY CombinatorYonjin CapitalYuhan USAZGC CapitalZJ Future



2019 Participating Companies

360MEDLINK712 NorthA2A PharmaceuticalsAbalone BioAbreos BiosciencesAccelero BiostructuresAccuitisAcquist TherapeuticsACS Brightedge FundACT GenomicsActinium PharmaceuticalsActoBio TherapeuticsAdjuvance TechnologiesAethlon MedicalAhead Therapeutics SLAIMM TherapeuticsAiVita BiomedicalAllen Institute For Brain ScienceAllogene TherapeuticsAlpha Cancer TechnologiesAlpine Immune SciencesAltimmuneAmerican Gence Technologies

InternationanlAmma TherapeuticsAmnicellAMPsource BiopharmaAMRA MedicalAmygdala NeurosciencesAnima BiotechAnnexon BiosciencesAntevAntidote TechnologiesAon Risk SolutionsAposenseArcturus TherapeuticsArdigenAristea TherapeuticsAro BiotherapeuticsAspect BiosystemsAstraZenecaAttentive TherapeuticsAuransaAurora BioAvail BioAvails MedicalAvisa PharmaAxeroVisionBastion BiologicsBCell SolutionsBilixBill and Melinda Gates FoundationBioCenturyBioMarker StrategiesBioMotivBioSuperior Technology

Bioxceed Innovation HubBioXcel TherapeuticsBipharmBird Rock BioBlackThorn TherapeuticsBloom ScienceBoundless Bio Brava DiagnosticsBreakthrough GenomicsBridgeBio PharmaBridGene BiosciencesBristol-Myers Squibb CompanyBusiness FranceCalifornia Institute for Regenerative

MedicineCambia GroveCanaccord GenuityCantabio PharmaceuticalsCardiogas TechnologiesCaribou BiosciencesCarmell TherapeuticsCatalyst PharmaceuticalsCell Care TherapeuticsCelularityCentury TherapeuticsCerevanceCerSci TherapeuticsCesca TherapeuticsChubbCircle PharmaCircumventCity of HopeClick TherapeuticsClinical Network Services (CNS) CODA BiotherapeuticsCohBarCommon PharmaContralineCorrelia BiosystemsCortexymeCorvidia TherapeuticsCourier TherapeuticsCue BiopharmaCystic Fibrosis FoundationCytoDynCytonus TherapeuticsCytovia TherapeuticsDa VolterraDalriada TherapeuticsDalton BioanalyticsDaré BioscienceDeallus ConsultingDeBiopharm InternationalDeciduous TherapeuticsDecoy BiosystemsDeep Lens

DelNovaDelta-Fly PharmaDemurisDia-beat-itDNALite TherapeuticsDOTBIODrusolv TherapeuticsDyadic InternationalDyve BiosciencesEA PharmaEconomic Development Agency

BrandenburgEdesa BiotechElevianElex BiotechEli Lilly and CompanyEngineBioEngrail TherapeuticsEnsysce BiosciencesEnterTroy BioEpic SciencesEpilepsy FoundationEquilliumEspero BioPharmaethris GmbHEureka TherapeuticsEvaluateExicureExxel PharmaFacile TherapeuticsFellow HealthFenologica BiosciencesFibrocell ScienceFirst Light DiagnosticsForesee PharmaceuticalsFortress BiotechGalimedix TherapeuticsGel4MedGLAdiator BiosciencesGlobalConnectWorksGlobalDataGlyTechGolden Biotechnology Corp.Greenwich LifeSciencesH.C. Wainwright & CompanyHalloran Consulting GroupHalo BiosciencesHaystack SciencesHeartseedHelixmith Co.Hercules CapitalHistogenHoneylabHyaloric Biotech Hygieia Biological LaboratoriesIACTA Pharmaceuticals

Illumina VenturesIlya PharmaImmunoMet TherapeuticsImmunophotonicsImpact TherapeuticsImpel NeuroPharmaIMVInCarda TherapeuticsIncysus TherapeuticsInformaInMed PharmaceuticalsInnofly ManagementInnovate BiopharmaceuticalsIntabioInterface BiologicsInterVenn BiosciencesInveniAIInversago PharmaInvivo SciencesISOThriveJaan BiotherapeuticsJT PharmaKaléo PharmaKedalion TherapeuticsKelun PharmaceuticalsKezar Life SciencesKinetaKinoxis TherapeuticsKissei AmericaKleo PharmaceuticalsKPI TherapeuticsKyorin USAL.E.K. ConsultingLandos BiopharmaLaVoieHealthScienceLeibniz Institute on AgingLeidosLempo TherapeuticsLexent BioLIPAC OncologyLocanaLocust WalkLonza Pharma & BiotechLSALung TherapeuticsLunitLynx BiosciencesMacDougall Biomedical

CommunicationsMAIA BiotechnologyMammoth BiosciencesMandalmedMantra BioMaxCyteMedsavanaMembio

3,150 BIO ONE-ON-ONE PARTNERING MEETINGS TOOK PLACE OVER THE TWO-DAY EVENT



2019 Participating Companies, CONTINUED

Merck KGaAMetcelaMetVitalMicroRadical 360Mitsubishi Tanabe PharmaMMSCMolecular TheranosticsMonash UniversityMorphocell TechnologiesMorrison & FoersterMUSC Foundation for Research

DevelopmentMycovia PharmaceuticalsNammi TherapeuticsNanosticsNational Institutes of Health, NHLBINational Taiwan University College of

MedicineNavidea BioPharmaceuticalsNavigant ConsultingNavigen PharmaceuticalsNB Health LaboratoryNDA GroupNelumNeOnc Technologies NeumentumNeuroBo PharmaceuticalsNeurocycle TherapeuticsNeuroscience Trials AustraliaNeuroscientific BiopharmaceuticalsNew Orleans Business AllianceNew5winNikon InstrumentsNkarta TherapeuticsNorth Carolina Biotechnology CenterNovelogics BiotechnologyNovotechNucleus NetworkNuvOx PharmaOkava PharmaceuticalsOmada HealthOncolytics BiotechOncolyze TherapeuticsOncomatryx Biopharma

OncoSenXOpiant PharmaceuticalsOpus Biotech CommunicationsOragenicsOrion BiotechnologyOrthoMedOrthopaedic Research and Education

FoundationOrthoTrophixOxSonics TherapeuticsOxStem LimitedPacylex PharmaceuticalsPAION AGPanjab UniversityParas Biopharmaceuticals Finland OyPhanes TherapeuticsPhenomic AIPhosplatin TherapeuticsPrivo TechnologiesProteinaQuadriga BiosciencesRafael PharmaceuticalsRakuten Medical Japan K.K.Rejuvenation TechnologiesResverlogix CorporationRetrotopeRiptide BioscienceRubrYc TherapeuticsSAB BiotherapeuticsSapience TherapeuticsSatellos BioscienceSatsuma PharmaceuticalsSCIBACSeelos TherapeuticsSEngine Precision MedicineSENS Research FoundationSenti BiosciencesSentien BiotechnologiesSerimmuneSFA TherapeuticsShareVaultShifa Biomedia CorporationShinkei TherapeuticsSiragen Pharmaceuticals

Sisu PharmaSmartPharma TherapeuticsSofinnova VenturesSpectrum PharmaceuticalsSpinalCyte, LLCSplash PharmaceuticalsStanford SPARK ProgramStanford UniversitySterling BayStero TherapeuticsStructure Based DesignSummit TherapeuticsSurrozenSymvivo CorporationSynDevRxSynthetic BiologicsSyntheXTampere UniversityTargetGene BiotechnologiesTechnology Venture

CommercializationTEGA TherapeuticsTeikoku Pharma USATempo TherapeuticsTerran BiosciencesTerumo BCTThe Money Channel NYCThe University of ChicagoThe University of Texas MD AndersonTheraTargetThinkCyteThrombo TherapeuticsTierra BiosciencesTIGAR HealthTorreyaToskTraffic TherapeuticsTranquis TherapeuticsTrilogy TherapeuticsTriursus TherapeuticsTrovaGeneTrue Bearing DiagnosticsTulane University School of MedicineU.S. Pharmacopeial

UC Davis-Office of ResearchUltivueUniversity of California, DavisUniversity of California, San FranciscoUniversity of Colorado Anschutz

Medical CampusUniversity of MichiganUniversity of OsloUniversity of Texas at AustinUniversity of Texas, MD Anderson

Cancer CenterUniversity of the Sunshine Coast

Clinical Trials CentreUniversity of TsukubaUniversity of Utah TVCUnivfyUnnatural ProductsValitorValley Fever SolutionsValtari BioVaporoxVarsona PharmaceuticalsVelosBioVenture ValuationVida Strategic PartnersviDA TherapeuticsVigeo TherapeuticsViramalVistara BiosciencesVitriVaxVM OncologyVona OncologyVybionWenbli TherapeuticsWheelhousexCella BiosciencesXoc PharmaceuticalsXontogenyX-ThermaYivivaZenith EpigeneticsZenopharm

2020 Planning Timeline

June – July August – September October

• Registration Opens• BIO Discount Housing Block Opens• Apply for a Company Presentation

• Early Bird Registration Rate Ends• Buzz of BIO Competition• BIO One-on-One Partnering Opens

• BIO Investor Forum, Westin St. Francis Hotel



Mahima Agochiya, PhDBusiness Development & Program ManagerSPARK Translational Research Program, Stanford University

Shelley Chu, MD, PhDPartnerAbingworth

Tao Huang, PhD, JDVenture PartnerCenova Capital

Jennifer LandressSenior Vice President and Chief Operating OfficerBiocom

Janice BourqueManaging Director, Life SciencesHercules Technology Growth Capital

Rajeev Dadoo, PhDPartnerS.R. One Limited

Charlotte Hubbert, PhDPartnerGates Foundation Venture Capital

Bill Martin, PhDPresident and Chief Operating OfficerBlackthorn Therapeutics

Alice Chen, PhDVice PresidentAccelerator Life Science Partners

Jack FlorioPartner, Strategy Consulting PracticeDeallus

Margaret KimExecutive Director, Life SciencesJPMorgan Chase & Co.

Carolyn Ng, PhDManaging DirectorVertex Ventures HC

Jason CammManaging Director and Chief Medical OfficerThiel Capital LLC

Gini Deshpande, PhDFounder & Chief Executive OfficerNuMedii

Alexis Ji, PhDPartnerIllumina Ventures

Samantha Miller, MSc, MBACo-Founder and Chief Operating Officer, Cadence Health; Chief Business OfficerInCarda Therapeutics

Jung ChoiChief Business & Strategy OfficerGlobal Blood Therapeutics

Julie Gilmore, PhDChief Operating Officer, Lilly Research LabsEli Lilly and Company

Ravi Kiron, PhDHead, BioPharma External InnovationEMD Serono

Peter Noymer, PhDFormer President and CEOKedalion Therapeutics; Independent Advisor

2019 Advisory Committee



Stephen RitochChairman & Chief Executive OfficerBlaise Group International

Komathi StemFounder & Chief Executive OfficermonARC Bionetworks

John RyanManaging DirectorWells Fargo Strategic Capital

Samuel Wu, MD, PhDManaging DirectorAcuris Partners

Mahendra G. Shah, PhDManaging DirectorVivo Capital

Andrew SetikasSenior Vice President, Business Development and StrategyCalifornia Life Sciences Association

Asish Xavier, PhDVice President, Venture InvestmentsJohnson & Johnson Innovation – JJDC, Inc.

Ruchita SinhaSenior Director of InvestmentsSanofi Ventures

2019 Advisory Committee, CONTINUED

BIO Members enjoy a significant discount on conference registration rates. BIO is the only global organization that brings together biotech innovators focused on accelerating the progress of new therapeutic technologies into commercialization and treating patients.



2019 Sponsors

CONFERENCE SPONSORS

DOUBLE HELIX SPONSORS

SUPPORTING BANK SPONSOR



Price(USD)

Number of Registrations

Recognition on Conference

Website, Materials and

Signage

Acces to BIO One-on-One Partnering

Partnering Suite and Priority

Scheduling of Meetings

Guaranteed Speaking

Opportunity

Showcase Thought Leadership

Program Sponsor $25,000 3 ✔ ✔ ✔ ✔

Company Presentations Sponsor $20,000 2 ✔ ✔

Access Your Target Audience

Welcome Reception Sponsor $17,500 2 ✔ ✔

Hospitality Sponsor $15,000 2 ✔ ✔

BIO SPARK Showcase Reception Sponsor $12,500 2 ✔ ✔

BIO Showcase Tabletop Exhibit Sponsor $7,500 1 ✔

Maximize Partnering & Deal Making

BIO One-on-One Partnering System Sponsor $20,000 3 ✔ ✔ ✔

Partnering Suite Sponsor $17,500 2 ✔ ✔ ✔

Partnering Lounge Sponsor $12,500 2 ✔ ✔ ✔

Boost Brand Visibility

Conference Bag Sponsor $17,500 2 ✔ ✔

Lanyard Sponsor $15,000 2 ✔ ✔

WiFi Sponsor $12,500 2 ✔ ✔

Buzz of BIO Contest Sponsor $7,500 1 ✔

Social Media Sponsor $7,500 1 ✔

Daily Buzz Email Sponsor $7,500 1 ✔

Sponsorship Opportunities & Benefits Breakdown

Our Sales & Sponsorship team is always ready to support your event engagement. Please feel free to reach out to the team at +1.202.312.9264 or [email protected].



accelerate discovery. amplify returns. 2020 event overview.pdf · santen pharmaceutical co. santen...

Documents